Pregnancy vaccine shields babies from RSV? new study investigates
NCT ID NCT06813872
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the ABRYSVO vaccine, given to pregnant women, protects their babies from RSV, a leading cause of severe lung infections in infants. Researchers will analyze medical records of infants up to 6 months old in western Pennsylvania over several RSV seasons. No new participants are enrolled; the study uses existing data to measure vaccine effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABRYSVO (RSV vaccine given during pregnancy)
- What this could lead to
- If successful, this could confirm that vaccinating pregnant women with ABRYSVO effectively prevents severe RSV in newborns, supporting wider vaccine use.
- What could go wrong
- This is a small, observational study in one region, so results may not apply everywhere. Real-world effectiveness can vary, and the study does not test new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUSES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.